Big Ten Cancer Research Consortium Newsletter

December 2016 Newsletter

Open to Accrual

BTCRC-BRE15-016

Sponsor-Investigator:
Oana Danciu, MD (Illinois)
Project Management:
Ahran Lee
e: [email protected]
p: 317-634-5842, ext. 14
Web Resources:
clinicaltrials.gov: NCT02668666
BTCRC Study Web Page

BTCRC-ESO14-012

Sponsor-Investigator:
Shadia Jalal, MD (Indiana)
Project Management:
Ahran Lee
e: [email protected]
p: 317-634-5842, ext. 14
Web Resources:
clinicaltrials.gov: NCT02639065

BTCRC-GI13-002

Sponsor-Investigator:
Bert O'Neil, MD (Indiana)
Project Management:
Michael Nunley
e: [email protected]
p: 317-634-5842, ext. 17
Web Resources:
clinicaltrials.gov: NCT02575339
BTCRC Study Web Page

BTCRC-GU15-023

Sponsor-Investigator:
Monika Joshi, MD (Penn State)
Project Management:
Dana Musapatika
e: [email protected]
p: 317-634-5842, ext. 39
Web Resources:
clinicaltrials.gov: NCT02891161
BTCRC Study Web Page

Closed to Accrual

BTCRC-GU14-003

Sponsor-Investigator:
Arkadiusz Dudek, MD, PhD (Illinois)
Project Management:
Michael Nunley
e: [email protected]
p: 317-634-5842, ext. 17
Web Resources:
clinicaltrials.gov: NCT02348008
BTCRC Study Web Page

Approved LOI

BTCRC-BRE15-024

Adv. AR+ triple neg. breast cancer
Sponsor-Investigator:
Ruth O'Regan, MD (Wisconsin)

BTCRC-BRE16-042

Adv. HR+ HER2- breast cancer
Sponsor-Investigator:
Nancy Chan, MD (Rutgers)

BTCRC-GI15-015

Adv. gastric, gastroesophageal junction cancer
Sponsor-Investigator:
Halla Nimeiri, MD
(Northwestern)

BTCRC-GI16-030

Adv. pancreatic cancer
Sponsor-Investigator:
Safi Shahda, MD (Indiana)

BTCRC-GU16-043

Adv. kidney cancer
Sponsor-Investigator:
Ajjai Alva, MBBS (Michigan)

BTCRC-GYN15-013

Adv./recurrent endometrial cancer
Sponsor-Investigator:
Mario Pineda, MD, PhD
(Northwestern)

BTCRC-HEM15-028

Relapsed/refractory peripheral
T-cell lymphoma
Sponsor-Investigator:
Ryan Wilcox, MD, PhD (Michigan)

BTCRC-HEM16-055

Relapsed/refractory Hodgkin lymphoma
Sponsor-Investigator:
Tycel Phillips, MD (Michigan)

BTCRC-LUN15-017

Non-small cell lung cancer
Sponsor-Investigator:
Lawrence Feldman, MD (Illinois)

BTCRC-LUN15-025

Mesothelioma
Sponsor-Investigator:
Arkadiusz Dudek, MD, PhD (Illinois)

BTCRC-LUN15-029

Adv. non-small cell lung cancer
Sponsor-Investigator:
Greg Durm, MD (Indiana)

Research Development

To Discuss Protocols: Contact Jessica Roy at [email protected] or 317-634-5842, ext. 19

To Join a Clinical Trial Working Group or Submit an LOI: Contact Anita Borek at [email protected] or 317-634-5842, ext. 48.

Support the BTCRC

Team up with the Big Ten Cancer Research Consortium. Together, we can make a big impact!

DUART study combines radiation, immunotherapy in adv. bladder cancer

A new Big Ten Cancer Research Consortium study, led by Monika Joshi, MD, MRCP, of Penn State Cancer Institute, is now open to accrual. BTCRC-GU15-023 is a phase Ib/II study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial cancer of the bladder. The study is open at Penn State Cancer Institute, and additional BTCRC member sites are expected to open in the near future.

Read more .

Steering Committee appoints
chair, vice chair

Members of the Big Ten Cancer Research Consortium Steering Committee recently appointed Robert Kratzke, MD, as the committee's first chair, and Ruth O'Regan, MD, as its vice chair. Each will serve a one-year term, with Dr. O'Regan serving as chair in the subsequent year.

Dr. Kratzke is associate professor in the Department of Medicine at the Masonic Cancer Center, University of Minnesota.

Dr. O'Regan is professor and division head of hematology and oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health.

Diversity in clinical trial participation

Studies show that patients with low income, the elderly, racial and ethnic minorities, women, and those who live in rural areas represent the smallest percentage of clinical trial participants. Unfortunately, these groups also represent a disproportionate burden of disease. A diverse coalition of health care partners that includes the Big Ten Cancer Research Consortium launched the #BeAGift awareness campaign aimed at changing perceptions of and encouraging participation in clinical trials.

Learn more .

New Clinical Trial Working Groups

The Big Ten Cancer Research Consortium invites junior and senior faculty investigators, scientists, and fellows to join the following Clinical Trial Working Groups that are now being formed:

Immunotherapy
Hematopoietic Stem Cell Transplant

To join these or other Clinical Trial Working Groups, contact [email protected], or click the button below.

We're Teaming Up!

Members of the BTCRC's lymphoid, myeloid, and multiple myeloma working groups met during the ASH Annual Meeting (pictured) to discuss study concepts and trials in development.

The BTCRC's Breast Clinical Trial Working Group also met during the San Antonio Breast Cancer Research Symposium.

Member Features

University of Wisconsin Carbone Cancer Center

Get to know Natalie Callander, MD (left) , a hematologist at the University of Wisconsin Carbone Cancer Center and member of the BTCRC's Multiple Myeloma Clinical Trial Working Group.

Vaishalee Kenkre, MD (right), an assistant professor of medicine in the division of hematology/oncology at the UW School of Medicine and Public Health, discusses a novel strategy to reduced GVHD in lymphoma transplantations. Dr. Kenkre is a member of the BTCRC's Lymphoid Malignancies Clinical Trial Working Group.